Mathematical modeling of three years of follow-up data stemming from an earlier phase 2b trial found that anti-CSP antibody titers satisfy the criteria for an immunological correlate of protection for R21/Matrix-M vaccine efficacy against clinical malaria (Schmit et al., 2024). The gene discussed is DNAJC5; the disease is malaria.